Cover Image
市場調查報告書

Glimepiride的中國市場

Investigation Report on China's Glimepiride Market, 2018-2022

出版商 China Research and Intelligence 商品編碼 334099
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Glimepiride的中國市場 Investigation Report on China's Glimepiride Market, 2018-2022
出版日期: 2018年11月29日 內容資訊: 英文 30 Pages
簡介

中國的Glimepiride銷售額從2005年到2014年以30.7%的年複合成長率擴大,到2014年達成了2億2400萬人民幣的規模。

本報告提供中國的Glimepiride市場相關調查,提供您Glimepiride的功用·效果,中國市場上的專利及核准狀況,銷售額·銷售量的變化與預測,價格趨勢,並彙整主要製造商與市場佔有率,競爭環境及其展望,主要製造商簡介等資料。

第1章 Glimepiride的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Glimepiride的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Glimepiride銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Glimepiride的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Glimepiride劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為準
  • 各劑型的市場佔有率:以銷售量為準

第6章 中國的醫院的Glimepiride的標準價格

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd (商品名:Amaryl)
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd
  • Sichuan Pudu Pharmaceutical Plant

第7章 中國市場中Glimepiride的主要製藥公司

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd

第8章 中國的Glimepiride的市場預測

  • 市場規模的預測
  • 競爭情形的預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1811352

Description

Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi's brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to CRI, with the development of China's economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to CRI, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Amaryl captured more than 80% share of China's Glimepiride market.

It is expected that as the number of diabetics continues to grow, China's Glimepiride market will have huge growth potential in the next few years.

Topics Covered:

  • Situation of diabetes in China
  • Sales of Glimepiride in China
  • Competition on China's Glimepiride market
  • Prices of Glimepiride in China
  • Forecasts on China's Glimepiride market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Glimepiride

  • 1.1 Indications for Glimepiride
  • 1.2 Development of Glimepiride in China
  • 1.3 Governmental Approval of Glimepiride in China

2 Sales of Glimepiride in China, 2013-2017

  • 2.1 Sales Value of Glimepiride
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Glimepiride
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules
    • 2.3.3 Pills

3 Analysis on Major Glimepiride Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Glimepiride Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Sanofi (Beijing) Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in China
  • 3.3 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in China
  • 3.4 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
  • 3.5 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.
  • 3.6 Sanofi

4 Prices of Glimepiride in China, 2017-2018

  • 4.1 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Amaryl)
  • 4.2 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Wansuping)
  • 4.3 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Linmeixin)
  • 4.4 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. (Yousu)
  • 4.5 Sanofi (Amaryl)

5 Prospect of China's Glimepiride Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Sales of Glimepiride in China, 2013-2017
  • Chart Sales Value of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Volume of Glimepiride in China, 2013-2017
  • Chart Sales Volume of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Value of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Volume of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Value of Glimepiride Capsules in China, 2013-2017
  • Chart Sales Value of Glimepiride Pills in China, 2013-2017
  • Chart Sales Volume of Glimepiride Pills in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Volume of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Sanofi's Glimepiride, 2013-2017
  • Chart Prices of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Sanofi's Glimepiride in Parts of China, 2017-2018
Back to Top